Turn Therapeutics Inc.
TTRX
$3.98
$0.102.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 308.93% | 166.10% | 100.40% | 1.84% | -35.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 289.04% | 141.93% | 102.29% | 13.33% | -23.76% |
| Operating Income | -289.04% | -141.93% | -102.29% | -13.33% | 23.76% |
| Income Before Tax | -110.89% | -132.98% | -91.26% | -8.86% | 24.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.89% | -132.98% | -91.26% | -8.86% | 24.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.89% | -132.98% | -91.26% | -8.86% | 24.49% |
| EBIT | -289.04% | -141.93% | -102.29% | -13.33% | 23.76% |
| EBITDA | -296.76% | -144.90% | -104.23% | -13.26% | 24.38% |
| EPS Basic | -103.38% | -123.84% | -86.07% | -7.18% | 24.94% |
| Normalized Basic EPS | -103.45% | -124.24% | -86.79% | -7.39% | 24.81% |
| EPS Diluted | -103.38% | -123.84% | -86.07% | -7.18% | 24.94% |
| Normalized Diluted EPS | -103.45% | -124.24% | -86.79% | -7.39% | 24.81% |
| Average Basic Shares Outstanding | 4.24% | 3.26% | 2.16% | 1.23% | 0.56% |
| Average Diluted Shares Outstanding | 4.24% | 3.26% | 2.16% | 1.23% | 0.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |